Literature DB >> 19429061

Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors.

Satoshi Yamamura1, Hiromitsu Saito, Noboru Suzuki, Sanae Kashimoto, Tatsuya Hamaguchi, Keiko Ohoyama, Dai Suzuki, Shinich Kanehara, Masanori Nakagawa, Takashi Shiroyama, Motohiro Okada.   

Abstract

To clarify the antiepileptic mechanisms of zonisamide (ZNS), we determined the interaction between ZNS and inositol-1,4,5-triphosphate receptor (IP3R) on exocytosis of GABA and glutamate in rat frontal cortex using microdialysis. ZNS increased basal GABA release, but not glutamate, concentration-dependently, and reduced concentration-dependently K(+)-evoked GABA and glutamate releases. Inhibition and activation of IP3R reduced and enhanced basal and K(+)-evoked GABA releases, respectively. The K(+)-evoked glutamate release was reduced and enhanced by IP3R antagonist and agonist, respectively, whereas basal glutamate release was increased by IP3R agonist but not affected by IP3R antagonist. Under extracellular Ca(2+) depletion, IP3R agonist increased basal GABA and glutamate releases. The latter effects of IP3R agonist were weakly enhanced by ZNS, but such stimulatory action of ZNS was abolished by extracellular Ca(2+) depletion. In contrast, ZNS inhibited the stimulatory effect of IP3R agonist on K(+)-evoked release. The stimulatory effect of IP3R agonist on basal release was regulated by N-type voltage-sensitive Ca(2+) channel (VSCC) rather than P- and L-type VSCCs, whereas the stimulatory effect of IP3R agonist on K(+)-evoked release was regulated by P- and L-type VSCCs rather than N-type VSCC. These results suggest that ZNS-activated N-type VSCC enhances IP3R-associated neurotransmitter release during resting stage, whereas ZNS-induced suppression of P- and L-type VSCCs possibly attenuates IP3R-associated neurotransmitter release during neuronal hyperexcitability. Therefore, the combination of both of these two actions of ZNS on IP3R-associated neurotransmitter release mechanism seems to be involved, at least in part, in the mechanisms of antiepileptic and neuroprotective actions of ZNS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19429061     DOI: 10.1016/j.neulet.2009.02.065

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Placebo-controlled trial of zonisamide for the treatment of alcohol dependence.

Authors:  Albert J Arias; Richard Feinn; Cheryl Oncken; Jonathan Covault; Henry R Kranzler
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

2.  Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

3.  Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.

Authors:  Kelly E Dunn; Taylor F Marcus; Cynthia Kim; Jennifer R Schroeder; Ryan Vandrey; Annie Umbricht
Journal:  Nicotine Tob Res       Date:  2015-10-17       Impact factor: 4.244

4.  Transcriptomic analysis in a Drosophila model identifies previously implicated and novel pathways in the therapeutic mechanism in neuropsychiatric disorders.

Authors:  Priyanka Singh; Farhan Mohammad; Abhay Sharma
Journal:  Front Neurosci       Date:  2011-03-31       Impact factor: 4.677

5.  A Novel Sulfonamide, 4-FS, Reduces Ethanol Drinking and Physical Withdrawal Associated With Ethanol Dependence.

Authors:  Muhammad Sona Khan; Wulfran Trenet; Nancy Xing; Britta Sibley; Muzaffar Abbas; Mariya Al-Rashida; Khalid Rauf; Chitra D Mandyam
Journal:  Int J Mol Sci       Date:  2020-06-21       Impact factor: 5.923

Review 6.  Carbonic Anhydrase Inhibitors and Epilepsy: State of the Art and Future Perspectives.

Authors:  Lidia Ciccone; Chiara Cerri; Susanna Nencetti; Elisabetta Orlandini
Journal:  Molecules       Date:  2021-10-22       Impact factor: 4.411

7.  Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant α4 subunit of nicotinic ACh receptor.

Authors:  Kouji Fukuyama; Masashi Fukuzawa; Takashi Shiroyama; Motohiro Okada
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

Review 8.  Anticonvulsant Effects of Carbonic Anhydrase Inhibitors: The Enigmatic Link Between Carbonic Anhydrases and Electrical Activity of the Brain.

Authors:  Hatice Zehra Ozsoy
Journal:  Neurochem Res       Date:  2021-07-05       Impact factor: 3.996

9.  Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats.

Authors:  Motohiro Okada; Ruri Okubo; Kouji Fukuyama
Journal:  Int J Mol Sci       Date:  2019-12-10       Impact factor: 5.923

10.  Effect of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide on Acquisition and Expression of Nicotine-Induced Behavioral Sensitization and Striatal Adenosine Levels.

Authors:  Naeem Ur Rehman; Muzaffar Abbas; Mariya Al-Rashida; Ahmed Tokhi; Muhammad Awais Arshid; Muhammad Sona Khan; Izhar Ahmad; Khalid Rauf
Journal:  Drug Des Devel Ther       Date:  2020-09-17       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.